|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Stanford University |
| Information provided by: | Stanford University |
| ClinicalTrials.gov Identifier: | NCT00230347 |
Purpose
This study is intended to establish the practicality of treating cancer in the liver with precisely administered single fractions of high-energy radiation using a radiosurgical (cross-firing) technique. A second purpose is to establish a safe dose for such therapy. Finally, the efficacy of radiosurgical ablation of liver tumors, in terms of radiographic response, will be measured.
| Condition | Intervention | Phase |
|
Cholangiocarcinoma Liver Cancer Adenocarcinoma |
Procedure: Stereotactic radiosurgery |
Phase I |
| MedlinePlus related topics: | Cancer Liver Cancer |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment |
| Official Title: | Dose Escalation Study Evaluating Stereotactic Radiosurgery for Liver Malignancies |
| Estimated Enrollment: | 20 |
| Study Start Date: | October 2003 |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:All the following criteria must be met:
Contacts and Locations| United States, California | |||||
| Stanford University School of Medicine | |||||
| Stanford, California, United States, 94305 | |||||
| Stanford University |
| Principal Investigator: | Albert Koong | Stanford University |
More Information
| Study ID Numbers: | HEP0003, HEP0003, NCT00230347 |
| First Received: | September 28, 2005 |
| Last Updated: | June 25, 2008 |
| ClinicalTrials.gov Identifier: | NCT00230347 |
| Health Authority: | USA:Institutional Review Board |
|
|
|